Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Haim Bio Ltd. is currently overseeing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner and 1 distinct art unit. This profile shows a highly targeted prosecution strategy, with the company's immediate patent office activity limited to a single technical matter.
The busiest examiner for Haim Bio Ltd. is GALSTER, SAMUEL LEONARD, who is managing 1 pending office action. This single action constitutes the total pending workload for the company. With only 1 distinct examiner and 1 distinct art unit involved, the company's progress in the Biotechnology & Pharmaceuticals sector is tied to this specific examination process.
The 1 pending office action requires a focused technical response to the 1 distinct art unit's requirements. GALSTER, SAMUEL LEONARD is the sole point of contact for the company's current patent applications. This streamlined prosecution environment allows the company to dedicate its full attention to the 1 pending office action currently under review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722680 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SGLT-2 INHIBITOR AND GOSSYPOL | GALSTER, SAMUEL LEONARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722680 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SGLT-2 INHIBITOR AND GOSSYPOL | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18722680 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SGLT-2 INHIBITOR AND GOSSYPOL | GALSTER, SAMUEL LEONARD | 1693 | §103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHaim Bio Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samuel Leonard Galster has the most, with 1 of Haim Bio Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
